Anderson G W, Heath D G, Bolt C R, Welkos S L, Friedlander A M
Bacteriology Division, U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21702-5011, USA.
Am J Trop Med Hyg. 1998 Jun;58(6):793-9. doi: 10.4269/ajtmh.1998.58.793.
A single, subcutaneous, 30-microg dose of either a combination of the Yersinia pestis proteins F1+V or a F1-V fusion protein adsorbed to the adjuvant aluminum hydroxide, protected Hsd:ND4 mice for one year against pneumonic plague. The recombinant F1+V vaccine provided significant protection as early as day 14 postimmunization. The current Plague Vaccine USP in a single 0.2-ml dose did not provide significant protection in this mouse model. Antibody titers to F1 and V peaked at approximately 5-12 weeks postimmunization and were still detectable one year later. These F1 and V subunit vaccines may offer effective long-term immunity with a reduced dosage schedule when compared with the presently licensed, formalin-killed, whole-cell vaccine.
皮下注射单剂量30微克的鼠疫耶尔森菌蛋白F1 + V组合或吸附于佐剂氢氧化铝的F1-V融合蛋白,可使Hsd:ND4小鼠获得为期一年的肺鼠疫免疫保护。重组F1 + V疫苗在免疫后第14天就提供了显著的保护作用。在该小鼠模型中,当前单剂量0.2毫升的美国药典鼠疫疫苗未提供显著保护。针对F1和V的抗体滴度在免疫后约5 - 12周达到峰值,一年后仍可检测到。与目前许可使用的福尔马林灭活全细胞疫苗相比,这些F1和V亚单位疫苗可能以减少的给药方案提供有效的长期免疫力。